Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation

The US Medicare agency intends to treat all dosage forms of the same active ingredient as a single drug for purposes of its new price negotiation authority. The approach will have implications for product branding and line extension strategies.

wide net
CMS is casting a wide net on dosage forms, branding and indications as it prepares for Rx price negotiations. • Source: Shutterstock

The US Medicare agency is casting a very broad net to ensure that all versions of the same active ingredient are included in the price negotiation process, regardless of differences in dosage form, branding, indications, or regulatory pathway.

In an implementation guidance released on 15 March, the Centers for Medicare & Medicaid Services makes clear that it...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet